Tailored anti-TNF therapy during pregnancy in patients with IBD: Maternal and fetal safety

Gut

Volumn 65, Issue 8, 2016, Pages 1261-1268

  De Lima, A ^a   Zelinkova, Z ^a,b   Van Der Ent, C ^a   Steegers, E A P ^a   Van Der Woude, C J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IBD Center   (Slovakia)

Author keywords

IBD

Indexed keywords

ADALIMUMAB; INFLIXIMAB; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR;

ADULT; ALLERGY; ARTICLE; BREAST FEEDING; CESAREAN SECTION; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG HYPERSENSITIVITY; DRUG SAFETY; ECZEMA; FEMALE; FETUS; FOLLOW UP; GESTATIONAL AGE; GROWTH RATE; HUMAN; INFANT; INFECTION RATE; INFLAMMATORY BOWEL DISEASE; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SMALL FOR DATE INFANT; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; VACCINATION REACTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; NETHERLANDS; NEWBORN; PREGNANCY COMPLICATIONS; PROCEDURES; PUERPERIUM;

ADALIMUMAB; ADULT; BREAST FEEDING; COHORT STUDIES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; NETHERLANDS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84930607964     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309321     Document Type: Article

References (31)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.e42; quiz e30.
2. Mahadevan U. Continuing immunomodulators and biologic medications in pregnant IBD patients-pro. Inflamm Bowel Dis 2007;13:1439-40.
3. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohns disease. Aliment Pharmacol Ther 2005;21:733-8.
4. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-Tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92; quiz e24.
5. Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17:1846-54.
6. Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-Tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013;11:318-21.
7. Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, et al. Pregnancy outcome following gestational exposure to TNF-Alpha-inhibitors: A prospective, comparative, observational study. Reprod Toxicol 2014;43:78-84.
8. Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011;33:1053-8.
9. Bortlik M, Duricova D, Machkova N, et al. Impact of anti-Tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-Term outcome of exposed children. Inflamm Bowel Dis 2014;20:495-501.
10. Guiddir T, Fremond ML, Triki TB, et al. Anti-TNF-Alpha Therapy May Cause Neonatal Neutropenia. Pediatrics 2014;134:e1189-93.
11. van der Woude CJ, Kolacek S, Dotan I, et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010;4:493-510.
12. van der Woude CJ, Ardizzone S, Bengtson MB, et al. The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease. J Crohns Colitis Published Online First: 26 Nov 2014 doi: 10.1093/eccojcc/jju006
13. Jaddoe VW, van Duijn CM, Franco OH, et al. The Generation R Study: design and cohort update 2012. Eur J Epidemiol 2012;27:739-56.
14. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohns disease. J Crohns Colitis 2013;7:736-43.
15. Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohns disease. Aliment Pharmacol Ther 2014;39:1126-35.
16. Battaglia FC, Lubchenco LO. A practical classification of newborn infants by weight and gestational age. J Pediatr 1967;71:159-63.
17. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
18. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohns disease. Gastroenterology 2004;126:402-13.
19. Soon IS, Molodecky NA, Rabi DM, et al. The relationship between urban environment and the inflammatory bowel diseases: A systematic review and meta-Analysis. BMC Gastroenterol 2012;12:51.
20. Mahadevan U, Martin CF, Sandler RS. PIANO, a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012;142(Suppl 1):S149.
21. Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012;2012:985646.
22. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003;21:3365-9.
23. Bengtson MB, Solberg IC, Aamodt G, et al. Relationships between inflammatory bowel disease and perinatal factors: both maternal and paternal disease are related to preterm birth of offspring. Inflamm Bowel Dis 2010;16:847-55.
24. Oron G, Yogev Y, Shkolnik S, et al. Inflammatory bowel disease: risk factors for adverse pregnancy outcome and the impact of maternal weight gain. J Matern Fetal Neonatal Med 2012;25:2256-60.
25. Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis 2011;17:795-801.
26. Stephansson O, Larsson H, Pedersen L, et al. Crohns disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol 2010;8:509-15.
27. Lin HC, Chiu CC, Chen SF, et al. Ulcerative colitis and pregnancy outcomes in an Asian population. Am J Gastroenterol 2010;105:387-94.
28. Broms G, Granath F, Linder M, et al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis 2014;20:1091-8.
29. Almasry SM, Eldomiaty MA, Elfayomy AK, et al. Expression pattern of tumor necrosis factor alpha in placentae of idiopathic fetal growth restriction. J Mol Histol 2012;43:253-61.
30. Cotechini T, Komisarenko M, Sperou A, et al. Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsia. J Exp Med 2014;211:165-79.
31. Lausten-Thomsen U, Olsen M, Greisen G, et al. Inflammatory markers in umbilical cord blood from small-for-gestational-Age newborns. Fetal Pediatr Pathol 2014;33:114-18.